拨康视云-B(02592.HK)向美国药管局提交有关CBT-199的新药临床试验申请

Core Viewpoint - The company announced that its wholly-owned subsidiary, ADS Therapeutics LLC, submitted a new drug clinical trial application for CBT-199, a potential best-in-class ophthalmic candidate, to the U.S. Food and Drug Administration (FDA) on December 15, 2025 [1]. Group 1 - The submission of the new drug clinical trial application marks a significant step in the development of CBT-199 [1]. - CBT-199 is being developed as a potential best-in-class treatment in the ophthalmic sector [1].